

Sandra Demaria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9300702/publications.pdf>

Version: 2024-02-01

177
papers

25,360
citations

16450
64
h-index

9588
142
g-index

184
all docs

184
docs citations

184
times ranked

23544
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	5.2	33
2	Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer. <i>Science Translational Medicine</i> , 2022, 14, eabe8195.	12.4	16
3	Radiation therapy-induced remodeling of the tumor immune microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 737-747.	9.6	30
4	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, 200.	4.4	0
5	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	4
6	Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 492-506.	0.8	42
7	Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 89-102.	3.4	39
8	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. <i>Onc Immunology</i> , 2021, 10, 1962592.	4.6	30
9	The role of radiotherapy in the age of immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 513-522.	1.3	28
10	Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer. , 2021, 9, e001717.		19
11	Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	111
12	Liver Metastasis Irradiation Can Restore Immunotherapeutic Responsiveness. <i>Trends in Immunology</i> , 2021, 42, 275-277.	6.8	0
13	Abstract PO-051: Radiation therapy enhances the presentation of phosphopeptides by MHC-I on cancer cells. , 2021, , .		0
14	Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?. , 2021, 9, e002038.		124
15	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd,) Tj ETQq1 1 0.784314 rgBT /Ov	4.4	1
16	Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides. <i>Trends in Cancer</i> , 2021, 7, 557-572.	7.4	33
17	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. <i>Nature Communications</i> , 2021, 12, 4447.	12.8	30
18	Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV-Challenged Nonhuman Primates. <i>Advanced Therapeutics</i> , 2021, 4, 2000163.	3.2	28

#	ARTICLE	IF	CITATIONS
19	560â€¦Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer. , 2021, 9, A589-A589.		0
20	Something Old and Something New to Unleash the Power of Natural Killer Cells Against Metastases. Cancer Immunology Research, 2021, , .	3.4	0
21	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	5.2	112
22	Aggressive Mammary Cancers Lacking Lymphocytic Infiltration Arise in Irradiated Mice and Can Be Prevented by Dietary Intervention. Cancer Immunology Research, 2020, 8, 217-229.	3.4	11
23	IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection. Oncoimmunology, 2020, 9, 1790716.	4.6	4
24	Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. Oncoimmunology, 2020, 9, 1830524.	4.6	34
25	Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. Pharmaceutics, 2020, 12, 981.	4.5	13
26	Perspectives in melanoma: meeting report from the â€œMelanoma Bridgeâ€•(December 5thâ€“7th, 2019,) Tj ETQq0 0 0 rgBT /Overlock	4.4	5
27	Future of Radiation and Immunotherapy. International Journal of Radiation Oncology Biology Physics, 2020, 108, 3-5.	0.8	21
28	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer, 2020, 6, 15.	5.2	16
29	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16.	5.2	90
30	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	5.2	106
31	Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses. Cancer Immunology Research, 2020, 8, 1054-1063.	3.4	31
32	Emerging Technologies for Local Cancer Treatment. Advanced Therapeutics, 2020, 3, 2000027.	3.2	37
33	Radiation-induced Adaptive Response: New Potential for Cancer Treatment. Clinical Cancer Research, 2020, 26, 5781-5790.	7.0	30
34	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€•1 and TILs as immunoâ€•oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	4.5	142
35	The abscopal effect 67 years later: from a side story to center stage. British Journal of Radiology, 2020, 93, 20200042.	2.2	73
36	CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection. Cancer Immunology Research, 2020, 8, 465-478.	3.4	87

#	ARTICLE	IF	CITATIONS
37	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
38	Immunogenic Cell Death Driven by Radiationâ€™Impact on the Tumor Microenvironment. Cancer Treatment and Research, 2020, 180, 281-296.	0.5	10
39	Exercise reduces immune suppression and breast cancer progression in a preclinical model. Oncotarget, 2020, 11, 452-461.	1.8	70
40	Abstract 1820: Art1, an extracellular mono-ADP-ribosyltransferase, is upregulated in response to cellular stress and promotes lung cancer growth. , 2020, , .		1
41	Abstract 2263: Characteristics of the interferon-stimulatory DNA cargo of exosomes produced by irradiated breast cancer cells. , 2020, , .		0
42	Abstract 2158: ART1 tumor expression mediates immune resistance in non-small cell lung cancer by elimination of P2 Å— 7R+ CD8 tissue resident memory T cells and conventional type I dendritic cells. , 2020, , .		0
43	822â€™...Local radiotherapy synergizes with tumor-specific TCR redirected T cells in the rejection of prostate cancer. , 2020, , .		0
44	459â€™...NK cells activation and recruitment to irradiated tumors is increased in the presence of IL-15. , 2020, , .		1
45	465â€™...Radiotherapy and CTLA-4 blockade expand anti-tumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection. , 2020, , .		0
46	The great debate at â€™Immunotherapy Bridge 2018â€™, Naples, November 29th, 2018. , 2019, 7, 221.		4
47	Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. , 2019, 7, 177.		32
48	Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Medicine, 2019, 11, 40.	8.2	179
49	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports, 2019, 9, 8572.	3.3	36
50	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 867-871.	6.3	41
51	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	1.6	505
52	Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial. , 2019, 7, 318.		12
53	Characterization of chemoradiation-induced changes in immune cells and targets for personalized therapy in locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2019, 37, 589-589.	1.6	15
54	Localizing radioimmunotherapy via nanochannel device for sustained intratumoral drug delivery for solid tumor treatment.. Journal of Clinical Oncology, 2019, 37, 37-37.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Focal Irradiation and Systemic TGF β 2 Blockade in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2493-2504.	7.0	201
56	Using immunotherapy to boost the abscopal effect. <i>Nature Reviews Cancer</i> , 2018, 18, 313-322.	28.4	844
57	Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2018, 52, 125-134.	9.6	51
58	Synergy Between Radiotherapy and Immunotherapy. , 2018, , 507-524.		0
59	The Future of Radiobiology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 329-340.	6.3	76
60	SnapShot: CGAS-STING Signaling. <i>Cell</i> , 2018, 173, 276-276.e1.	28.9	110
61	Radiation-Induced Long Noncoding RNAs in a Mouse Model after Whole-Body Irradiation. <i>Radiation Research</i> , 2018, 189, 251.	1.5	44
62	Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2018, 24, 259-265.	7.0	137
63	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	9.6	303
64	Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. <i>Cancer Immunology Research</i> , 2018, 6, 139-150.	3.4	172
65	Understanding Responses to Stereotactic Body Radiotherapy and Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2661-2662.	1.6	9
66	Radiotherapy induces responses of lung cancer to CTLA-4 blockade. <i>Nature Medicine</i> , 2018, 24, 1845-1851.	30.7	626
67	Microarray analysis of miRNA expression profiles following whole body irradiation in a mouse model. <i>Biomarkers</i> , 2018, 23, 689-703.	1.9	28
68	Cytosolic DNA Sensing in Organismal Tumor Control. <i>Cancer Cell</i> , 2018, 34, 361-378.	16.8	191
69	Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. <i>Trends in Immunology</i> , 2018, 39, 644-655.	6.8	312
70	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. <i>Onc Immunology</i> , 2018, 7, e1490854.	4.6	200
71	Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. <i>Cancer Immunology Research</i> , 2018, 6, 910-920.	3.4	245
72	Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 571-571.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Results of a phase II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. <i>Oncolmunology</i> , 2017, 6, e1274479.	4.6	10
74	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>European Journal of Cancer</i> , 2017, 81, 116-129.	2.8	443
75	TREX1 dictates the immune fate of irradiated cancer cells. <i>Oncolmunology</i> , 2017, 6, e1339857.	4.6	81
76	DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. <i>Nature Communications</i> , 2017, 8, 15618.	12.8	1,194
77	Heavy Metal to Rock the Immune Infiltrate. <i>Trends in Immunology</i> , 2017, 38, 539-541.	6.8	9
78	PTEN at the interface of immune tolerance and tumor suppression. <i>Frontiers in Biology</i> , 2017, 12, 163-174.	0.7	18
79	Immune recognition of irradiated cancer cells. <i>Immunological Reviews</i> , 2017, 280, 220-230.	6.0	73
80	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Oncolmunology</i> , 2017, 6, e1373237.	4.6	62
81	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.3	530
82	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.3	469
83	Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 247-258.	27.6	261
84	TREX1 is a checkpoint for innate immune sensing of DNA damage that fosters cancer immune resistance. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 509-515.	2.6	8
85	Barriers to Radiation-Induced In Situ Tumor Vaccination. <i>Frontiers in Immunology</i> , 2017, 8, 229.	4.8	149
86	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2017, 15, 223.	4.4	25
87	Therapeutic effect of local Interleukin-15 with radiotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 158-158.	1.6	1
88	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	5.5	230
89	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1845-1855.	7.0	242
90	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. <i>Cancer Immunology Research</i> , 2016, 4, 600-610.	3.4	86

#	ARTICLE	IF	CITATIONS
91	Radiotherapy: Changing the Game in Immunotherapy. Trends in Cancer, 2016, 2, 286-294.	7.4	270
92	Current clinical trials testing the combination of immunotherapy with radiotherapy. , 2016, 4, 51.		317
93	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology, 2016, 5, e1214790.	4.6	64
94	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. , 2016, 4, 37.		1
95	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	4.4	12
96	Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?. , 2016, 4, 29.		54
97	Subverting misconceptions about radiation therapy. Nature Immunology, 2016, 17, 345-345.	14.5	2
98	CD8+ T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy. EBioMedicine, 2016, 5, 59-67.	6.1	29
99	Abstract 4987: Role of the PD-1/PDL-1 pathway in resistance of patients with metastatic breast cancer to treatment with radiotherapy and TGF β 2 neutralization. , 2016, , .		0
100	TGF β 2 and activin A control regulatory T cells in irradiated tumors. , 2015, 3, .		1
101	Adenosine regulates radiation therapy-induced anti-tumor immunity. , 2015, 3, .		12
102	Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncology, The, 2015, 16, 795-803.	10.7	546
103	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine, 2015, 33, 7415-7422.	3.8	142
104	Mechanisms of synergy of radiotherapy and immunotherapy. Journal of Translational Medicine, 2015, 13, K5.	4.4	0
105	TGF β 2 Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Research, 2015, 75, 2232-2242.	0.9	429
106	Role of Local Radiation Therapy in Cancer Immunotherapy. JAMA Oncology, 2015, 1, 1325.	7.1	570
107	Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology, 2015, 4, e985930.	4.6	55
108	Combination of Radiotherapy and Immune Checkpoint Inhibitors. Seminars in Radiation Oncology, 2015, 25, 28-33.	2.2	121

#	ARTICLE	IF	CITATIONS
109	Current Clinical Trials Testing Combinations of Immunotherapy and Radiation. <i>Seminars in Radiation Oncology</i> , 2015, 25, 54-64.	2.2	123
110	Abstract 244: Abscopal responses in patients with refractory metastatic NSCLC treated with concurrent radiotherapy and CTLA-4 immune checkpoint blockade: evidence for the in situ vaccination hypothesis of radiotherapy. , 2015, , .		1
111	Abstract 2493: Fractionated but not single dose radiation is an optimal adjuvant for in situ tumor vaccination. , 2015, , .		1
112	Abstract 2856: Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade. , 2015, , .		1
113	Abstract 3329: Ionizing radiation modifies the molecular composition of exosomes derived from breast cancer cells. , 2015, , .		0
114	Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. <i>Oncology</i> , 2015, 29, 908-20, 922.	0.5	50
115	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmunology</i> , 2014, 3, e955691.	4.6	686
116	Densely Ionizing Radiation Acts via the Microenvironment to Promote Aggressive <i>Trp53</i>-Null Mammary Carcinomas. <i>Cancer Research</i> , 2014, 74, 7137-7148.	0.9	24
117	Combinations of Immunotherapy and Radiation in Cancer Therapy. <i>Frontiers in Oncology</i> , 2014, 4, 325.	2.8	205
118	Clinical Trial Evidence of the Antitumor Activity of Topical Imiquimod for Breast Cancer Skin Metastases. <i>Journal of Clinical Oncology</i> , 2014, 32, 3204-3205.	1.6	8
119	Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes. , 2014, 2, 37.		29
120	Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. <i>Oncolmunology</i> , 2014, 3, e28518.	4.6	439
121	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. <i>Journal of Clinical Oncology</i> , 2014, 32, 2959-2966.	1.6	1,080
122	Systems biology perspectives on the carcinogenic potential of radiation. <i>Journal of Radiation Research</i> , 2014, 55, i145-i154.	1.6	11
123	The Optimal Partnership of Radiation and Immunotherapy: from Preclinical Studies to Clinical Translation. <i>Radiation Research</i> , 2014, 182, 170-181.	1.5	80
124	Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade. , 2014, 2, .		6
125	Abstract 5020: Cooperative effects of programmed cell death-1 blockade and radiation in a model of a poorly immunogenic breast carcinoma. , 2014, , .		0
126	Abstract 633: Inhibition of TGF β 2 as a strategy to convert the irradiated tumor into in situ individualized vaccine. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
127	Immune Escape. , 2013, , 149-164.		1
128	Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift. Journal of the National Cancer Institute, 2013, 105, 256-265.	6.3	846
129	An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Nonâ€“Small Cell Lung Cancer. Cancer Immunology Research, 2013, 1, 365-372.	3.4	599
130	Radiotherapy Effects on Anti-Tumor Immunity: Implications for Cancer Treatment. Frontiers in Oncology, 2013, 3, 128.	2.8	55
131	Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology, 2013, 2, e23127.	4.6	34
132	The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology, 2013, 2, e25997.	4.6	30
133	Role of the crosstalk between CTLA-4 and NKG2D in the development of anti-CTLA-4 treatment strategies. Immunotherapy, 2013, 5, 109-112.	2.0	4
134	Novel combination of toll-like receptor (TLR)-7 agonist imiquimod and local radiotherapy in the treatment of breast cancer chest wall recurrences or skin metastases.. Journal of Clinical Oncology, 2013, 31, TPS3122-TPS3122.	1.6	1
135	Role of T lymphocytes in tumor response to radiotherapy. Frontiers in Oncology, 2012, 2, 95.	2.8	137
136	Synergy of Topical Toll-like Receptor 7 Agonist with Radiation and Low-Dose Cyclophosphamide in a Mouse Model of Cutaneous Breast Cancer. Clinical Cancer Research, 2012, 18, 6668-6678.	7.0	140
137	Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer. Clinical Cancer Research, 2012, 18, 6748-6757.	7.0	183
138	Invariant NKT Cells as Novel Targets for Immunotherapy in Solid Tumors. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	35
139	Radiation as an immunological adjuvant: current evidence on dose and fractionation. Frontiers in Oncology, 2012, 2, 153.	2.8	259
140	Radiation Therapy to Convert the Tumor Into an In Situ Vaccine. International Journal of Radiation Oncology Biology Physics, 2012, 84, 879-880.	0.8	244
141	The convergence of radiation and immunogenic cell death signaling pathways. Frontiers in Oncology, 2012, 2, 88.	2.8	220
142	Suppressing T cell motility induced by antiâ€“CTLA-4 monotherapy improves antitumor effects. Journal of Clinical Investigation, 2012, 122, 3718-3730.	8.2	167
143	The Numbers of FoxP3+ Lymphocytes in Sentinel Lymph Nodes of Breast Cancer Patients Correlate With Primary Tumor Size but Not Nodal Status. Cancer Investigation, 2011, 29, 419-425.	1.3	17
144	Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?. Cancer Immunology, Immunotherapy, 2011, 60, 999-1007.	4.2	27

#	ARTICLE	IF	CITATIONS
145	TGF β 1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells <i>In Vitro</i> and Promotes Tumor Control by Radiation <i>In Vivo</i> . Clinical Cancer Research, 2011, 17, 6754-6765.	7.0	217
146	Introduction to the Special BR-RIDGE Issue. Radiation Research, 2010, 173, 403-405.	1.5	0
147	Cancer and Inflammation: Promise for Biologic Therapy. Journal of Immunotherapy, 2010, 33, 335-351.	2.4	293
148	Radiotherapy Enhances Antitumor Effect of Anti-CD137 Therapy in a Mouse Glioma Model. Radiation Research, 2010, 173, 426-432.	1.5	68
149	Up-regulation of the Pro-inflammatory Chemokine CXCL16 is a Common Response of Tumor Cells to Ionizing Radiation. Radiation Research, 2010, 173, 418-425.	1.5	143
150	Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade. Clinical Cancer Research, 2009, 15, 597-606.	7.0	87
151	Research Highlights: Immunotherapy. Immunotherapy, 2009, 1, 733-736.	2.0	1
152	Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody. Clinical Cancer Research, 2009, 15, 5379-5388.	7.0	1,371
153	Systemic effects of local radiotherapy. Lancet Oncology, The, 2009, 10, 718-726.	10.7	822
154	Local control by radiotherapy: is that all there is?. Breast Cancer Research, 2008, 10, 215.	5.0	51
155	Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells. Journal of Immunology, 2008, 181, 3099-3107.	0.8	604
156	Effects of Chemoradiation on Tumor-Host Interactions: The Immunologic Side. Journal of Clinical Oncology, 2008, 26, 1562-1563.	1.6	35
157	Sensors of ionizing radiation effects on the immunological microenvironment of cancer. International Journal of Radiation Biology, 2007, 83, 819-825.	1.8	109
158	The Combination of Ionizing Radiation and Peripheral Vaccination Produces Long-term Survival of Mice Bearing Established Invasive GL261 Gliomas. Clinical Cancer Research, 2006, 12, 4730-4737.	7.0	151
159	Combining radiotherapy and immunotherapy: A revived partnership. International Journal of Radiation Oncology Biology Physics, 2005, 63, 655-666.	0.8	320
160	Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Laboratory Investigation, 2005, 85, 328-341.	3.7	149
161	Select forms of tumor cell apoptosis induce dendritic cell maturation. Journal of Leukocyte Biology, 2005, 77, 361-368.	3.3	54
162	Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clinical Cancer Research, 2005, 11, 728-34.	7.0	662

#	ARTICLE	IF	CITATIONS
163	HLA-A2-Restricted CD8 + -Cytotoxic-T-Cell Responses to Novel Epitopes in Mycobacterium tuberculosis Superoxide Dismutase, Alanine Dehydrogenase, and Glutamine Synthetase. Infection and Immunity, 2004, 72, 2412-2415.	2.2	52
164	Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. International Journal of Radiation Oncology Biology Physics, 2004, 58, 862-870.	0.8	1,166
165	Extracellular Processing of MHC Class I Antigens. , 2004, , 53-65.		1
166	Soluble HLA proteins with bound peptides are released from the cell surface by the membrane metalloproteinase. Human Immunology, 2000, 61, 1332-1338.	2.4	30
167	Fine Needle Aspiration of Primary Pleomorphic Liposarcoma of the Breast. Acta Cytologica, 1999, 43, 1131-1136.	1.3	8
168	Peptide-conformed \hat{I}^2 m-free class I heavy chains are intermediates in generation of soluble HLA by the membrane-bound metalloproteinase. Human Immunology, 1999, 60, 1216-1226.	2.4	17
169	Multilocular Thymic Cyst with Follicular Lymphoid Hyperplasia in a Male Infected with HIV. Acta Cytologica, 1999, 43, 1119-1123.	1.3	21
170	Soluble CD4 Induces the Binding of Human Immunodeficiency Virus Type 1 to Cells via the V3 Loop of Glycoprotein 120 and Specific Sites in Glycoprotein 41. AIDS Research and Human Retroviruses, 1996, 12, 281-290.	1.1	14
171	Bathophenanthroline Disulfonate and Soluble CD4 as Probes for Early Events of HIV Type 1 Entry. AIDS Research and Human Retroviruses, 1995, 11, 127-139.	1.1	7
172	CD8 and \hat{I}^2 -microglobulin-free MHC class I molecules in T cell immunoregulationMHC class I molecules in T cell immunoregulation. International Journal of Clinical and Laboratory Research, 1993, 23, 61-69.	1.0	25
173	The origin and fate of \hat{I}^2 m-free MHC class I molecules induced on activated T cells. Cellular Immunology, 1992, 142, 103-113.	3.0	54
174	Activation of human CD8-positive T cells via the CD8/HLA class I complex. Cellular Immunology, 1990, 126, 185-195.	3.0	5
175	Murine monoclonal antibodies as probes for the phenotypical, functional, and molecular analysis of a discrete peripheral blood lymphocyte population exerting natural killer activity in vitro. Human Immunology, 1985, 14, 87-102.	2.4	35
176	Cross-Talk of Breast Cancer Cells with the Immune System. , 0, , .		4
177	Local radiotherapy and GM-CSF in metastatic cancer: lessons from a proof of principle trial. OncolImmunology, 0, , 00-00.	4.6	1